Abbott Laboratories (ABT) has been under a strong bear grip, hence the stock is down -3.4% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 1.56% in the past 1 week. The stock has risen by 2.1% in the past week indicating that the buyers are active at lower levels, but the stock is down -5.36% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 1.37% and the 50-Day Moving Average is 3.08%.The 200 Day SMA reached 2.53% Abbott Laboratories is up 12.67% in the last 3-month period. Year-to-Date the stock performance stands at -5.03%.
Abbott Laboratories (ABT) stock is expected to deviate a maximum of $1.44 from the average target price of $48.46 for the short term period. 11 Street Experts have initiated coverage on the stock with the most promising target being $50 and the most muted being $45.
For the current week, the company shares have a recommendation consensus of Buy. Abbott Laboratories (NYSE:ABT): The stock opened at $40.95 and touched an intraday high of $42.03 on Friday. During the day, the stock corrected to an intraday low of $40.83, however, the bulls stepped in and pushed the price higher to close in the green at $41.87 with a gain of 1.82% for the day. The total traded volume for the day was 15,790,211. The stock had closed at $41.12 in the previous trading session.
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.